A Phase 2 interventional study of Fulvestrant in Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 35 sites in 8 countries. Open to female participants aged 45 Years to 130 Years. Per ClinicalTrials.gov, last updated 2020-01-06.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 35th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 21st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 45 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 64th largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2006, is one of 31 in phase 2, and was the 28th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fulvestrant 250 mg (intramuscular injection 250 mg)
Drug: Fulvestrant
Fulvestrant 250 mg (+ 250 mg loading regimen)
Drug: Fulvestrant
Fulvestrant 500 mg (intramuscular injection 500 mg)
Drug: Fulvestrant
intramuscular injection 250 mg \& 500 mg
Also known as: Faslodex, ZD9238
Objective Response (ORR)
Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions). All patients were to be followed up every 12 weeks for progression, defined by response evaluation criteria in solid tumors (RECIST v1.1).
Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Time to Progression (TTP)
Time from randomisation until objective disease progression or death (in the absence of objective progression) using the Kaplan-Meier method. RECIST tumor assessments were carried out every 12 weeks until progression.
Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Duration of Response (DoR)
DoR was defined as the time from date of first documentation of the response (CR or PR) until the date of disease progression or death from any cause.
Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Clinical Benefit Rate (CBR)
CBR was defined as the proportion of all randomised patients who had clinical benefit (response of CR, PR or SD\>=24 weeks.
Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body
A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean.
Time frame: Baseline to 12 weeks
Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes
A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean. The mean estimate of volume of distribution at steady state was reported as the sum of V1/F and V2/F in the clinical study report.
Time frame: Baseline to 12 weeks
Postmenopausal women with oestrogen receptor positive advanced breast cancer progressing or relapsing after previous endocrine therapy were randomised between 30th May 2006 and 30th November 2007
| Milestone | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Started | 47 | 51 | 46 |
| Completed | 11 | 17 | 14 |
| Not completed | 36 | 34 | 32 |
| Withdrew: Death | 2 | 4 | 2 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Disease progression | 31 | 26 | 27 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Incorrect enrollment | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Progression (investigators opinion) | 1 | 0 | 0 |
Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions). All patients were to be followed up every 12 weeks for progression, defined by response evaluation criteria in solid tumors (RECIST v1.1).
| Percentage of patients | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Objective Response (ORR) | 8.5 (2.4 to 20.4) | 5.9 (1.2 to 16.2) | 15.2 (6.3 to 28.9) |
Time from randomisation until objective disease progression or death (in the absence of objective progression) using the Kaplan-Meier method. RECIST tumor assessments were carried out every 12 weeks until progression.
| Days | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Time to Progression (TTP) | 88 (79 to 260) | 172 (80 to 339) | 169 (82 to 477) |
DoR was defined as the time from date of first documentation of the response (CR or PR) until the date of disease progression or death from any cause.
| Days | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Duration of Response (DoR) | NA (NA to NA) | NA (66 to NA) | 539 (539 to 539) |
CBR was defined as the proportion of all randomised patients who had clinical benefit (response of CR, PR or SD\>=24 weeks.
| Percentage of patients | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 31.9 (19.1 to 47.1) | 47.1 (32.9 to 61.5) | 47.8 (32.9 to 63.1) |
A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean.
| litres per hour | Fulvestrant |
|---|---|
| Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body | 31 ± 3.29 |
A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean. The mean estimate of volume of distribution at steady state was reported as the sum of V1/F and V2/F in the clinical study report.
| Liters | Fulvestrant |
|---|---|
| V1/F | 20600 ± 3.67 |
| V2/F | 35700 ± 27.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant 250 mg | 2/47 (4.3%) | 4/47 (8.5%) | 36/47 (76.6%) |
| Fulvestrant 250 mg + Loading Dose | 4/50 (8%) | 9/50 (18%) | 35/50 (70%) |
| Fulvestrant 500 mg | 2/46 (4.3%) | 4/46 (8.7%) | 31/46 (67.4%) |
| Event | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/47 | 2/50 | 0/46 |
| PainGeneral disorders | 0/47 | 0/50 | 1/46 |
| PneumoniaInfections and infestations | 0/47 | 0/50 | 1/46 |
| Hip FractureInjury, poisoning and procedural complications | 0/47 | 0/50 | 1/46 |
| AmnesiaNervous system disorders | 0/47 | 0/50 | 1/46 |
| Renal ColicRenal and urinary disorders | 0/47 | 0/50 | 1/46 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/47 | 1/50 | 1/46 |
| Macular HoleEye disorders | 1/47 | 0/50 | 0/46 |
| Meniscus LesionInjury, poisoning and procedural complications | 1/47 | 0/50 | 0/46 |
| Ischaemic StrokeNervous system disorders | 1/47 | 0/50 | 0/46 |
| Event | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 12/47 | 9/50 | 7/46 |
| FatigueGeneral disorders | 4/47 | 11/50 | 7/46 |
| Hot FlushVascular disorders | 9/47 | 5/50 | 3/46 |
| Back PainMusculoskeletal and connective tissue disorders | 5/47 | 8/50 | 7/46 |
| ConstipationGastrointestinal disorders | 3/47 | 7/50 | 1/46 |
| Injection Site PainGeneral disorders | 6/47 | 7/50 | 6/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/47 | 7/50 | 4/46 |
| DiarrhoeaGastrointestinal disorders | 3/47 | 4/50 | 6/46 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/47 | 1/50 | 2/46 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/47 | 6/50 | 4/46 |
| Age, Continuous(years) | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 9.9 | 68.1 ± 9.9 | 65.5 ± 9.0 | 65.8 ± 9.8 |
| Sex: Female, Male(Participants) | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg | Total |
|---|---|---|---|---|
| Female | 47 | 51 | 46 | 144 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg | Total |
|---|---|---|---|---|
| Caucasian | 45 | 51 | 46 | 142 |
| Oriental (Japanese) | 1 | 0 | 0 | 1 |
| Oriental (Asian other than Chinese or Japanese) | 1 | 0 | 0 | 1 |
Ran from May 2006 to primary completion in Jun 2008, 24 months.
Results were first posted in Aug 2011, 3 years 2 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 24 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant